CAR
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
SHANGHAI , Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR...
Read moreDetails
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR...
Read moreDetails
Why You Should Hold Avis Budget Stock in Your Portfolio Now
CAR benefits from strong demand, fleet management and technology investments, which boost profitability. However, lack of dividends and low liquidity...
Read moreDetails